KR20240158951A - 결정질 아티카프란트의 순수한 형태 - Google Patents

결정질 아티카프란트의 순수한 형태 Download PDF

Info

Publication number
KR20240158951A
KR20240158951A KR1020247033036A KR20247033036A KR20240158951A KR 20240158951 A KR20240158951 A KR 20240158951A KR 1020247033036 A KR1020247033036 A KR 1020247033036A KR 20247033036 A KR20247033036 A KR 20247033036A KR 20240158951 A KR20240158951 A KR 20240158951A
Authority
KR
South Korea
Prior art keywords
articaprant
composition
crystalline form
chemically
enantiomerically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247033036A
Other languages
English (en)
Korean (ko)
Inventor
리카르도 서몬트
마크 쉬밋
바니나 포포바
아담 사비츠
라마 멜코트
웨인 씨. 드레베츠
스리하리 고팔
데럴 펨버톤
차크라다르 라기셰티
아이바 케직
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Publication of KR20240158951A publication Critical patent/KR20240158951A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247033036A 2022-03-07 2023-03-06 결정질 아티카프란트의 순수한 형태 Pending KR20240158951A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317483P 2022-03-07 2022-03-07
US63/317,483 2022-03-07
PCT/IB2023/052082 WO2023170547A1 (en) 2022-03-07 2023-03-06 Pure forms of crystalline aticaprant

Publications (1)

Publication Number Publication Date
KR20240158951A true KR20240158951A (ko) 2024-11-05

Family

ID=85979414

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247033036A Pending KR20240158951A (ko) 2022-03-07 2023-03-06 결정질 아티카프란트의 순수한 형태

Country Status (15)

Country Link
US (2) US20230348377A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489748A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508071A (cg-RX-API-DMAC7.html)
KR (1) KR20240158951A (cg-RX-API-DMAC7.html)
CN (1) CN119156210A (cg-RX-API-DMAC7.html)
AU (1) AU2023231493A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254503A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002643A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012457A2 (cg-RX-API-DMAC7.html)
IL (1) IL315411A (cg-RX-API-DMAC7.html)
JO (1) JOP20240195A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010978A (cg-RX-API-DMAC7.html)
PE (1) PE20242109A1 (cg-RX-API-DMAC7.html)
TW (1) TW202345795A (cg-RX-API-DMAC7.html)
WO (1) WO2023170547A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709522B2 (en) * 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
WO2022234457A1 (en) * 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Also Published As

Publication number Publication date
PE20242109A1 (es) 2024-10-28
AU2023231493A1 (en) 2024-10-24
WO2023170547A1 (en) 2023-09-14
EP4489748A1 (en) 2025-01-15
JOP20240195A1 (ar) 2024-09-05
CO2024012457A2 (es) 2024-09-30
CL2024002643A1 (es) 2025-01-24
CA3254503A1 (en) 2023-09-14
TW202345795A (zh) 2023-12-01
MX2024010978A (es) 2024-12-06
US20230348377A1 (en) 2023-11-02
US20250326714A1 (en) 2025-10-23
CN119156210A (zh) 2024-12-17
IL315411A (en) 2024-11-01
JP2025508071A (ja) 2025-03-21

Similar Documents

Publication Publication Date Title
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
JP2025508071A (ja) 純粋な形態の結晶質アチカプラント
CA3179785A1 (en) Advantageous benzofuran compositions for mental disorders or enhancement
TW200914004A (en) (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
CN113271936A (zh) 治疗神经和精神疾病的方法
CN108883110A (zh) 使用食欲素-2受体拮抗剂治疗抑郁症的方法
JP2013539470A (ja) ロルカセリンと光学活性な酸との塩
KR20240152410A (ko) 아티카프란트를 포함하는 조성물
CA3219079A1 (en) Compositions and methods for the treatment of depression
US20250325515A1 (en) Forms Of Aticaprant
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
CA2808904A1 (en) Non-hygroscopic salts of 5-ht2c agonists
JP2021073171A (ja) (r)−ジミラセタム(1)と(s)−ジミラセタム(2)を非ラセミ比で含む相乗的組成物
CN103635190A (zh) 治疗方案
CN121969364A (zh) 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物
EP4479404A1 (en) Bridged ring compounds and their therapeutic use as cns agents
AU2024254600A1 (en) Advantageous fluorobenzofurans for the treatment of mental disorders or enhancement
HK1082411A1 (zh) 用於治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
HK1082411B (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000